DSIP Dosage: Community Sleep Protocols
Last updated May 19, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced
← DSIP encyclopedia entry · See also: Epithalon dosage · Regulatory tracker
DSIP is investigational and not FDA approved, and its human evidence is limited and mixed — even the sleep effect that gives it its name is not well established in people. There is no label or validated dose. The figures below reflect community practice, documented for education — not instructions for use.
The short version
DSIP (delta sleep-inducing peptide) is a naturally occurring nine–amino-acid peptide that got its name from early research linking it to deep, slow-wave (delta) sleep. It is used in community protocols for sleep and stress, but the honest framing is that decades after its discovery the human evidence remains thin and inconsistent — its effects are not as clearly established as the name implies, which is the key context for any dose.
What community protocols report
| Parameter | Commonly reported |
|---|---|
| Amount | ~100–500 mcg per dose |
| Frequency | Once daily |
| Timing | At bedtime |
| Route | Subcutaneous |
Bedtime dosing follows the obvious logic of a sleep peptide. But the modest microgram amounts and the bedtime timing are conventions inherited from how DSIP is discussed, not a schedule validated by robust human sleep studies — and the underlying effect itself is uncertain.
Where DSIP stands legally
DSIP was on the FDA 503A Category 2 list and, on April 15, 2026, was among the peptides removed from Category 2 after nominations were withdrawn — which is not approval. It is scheduled (under the name emideltide) for PCAC review on July 24, 2026. Until that concludes it remains outside the approved-medicine framework; see the Regulatory Status Tracker.
Reconstitution basics
DSIP is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water before a microgram dose can be measured. The Reconstitution Calculator converts vial strength and diluent volume into an exact syringe draw; it cannot verify the contents of an unregulated vial.
Frequently asked questions
Does DSIP reliably improve sleep?
The human evidence is limited and mixed; despite its name, a consistent, well-demonstrated sleep effect in people has not been firmly established.
Is it sedating like a sleep drug?
It is not a sedative-hypnotic and does not work like one; its proposed role relates to sleep-regulating signaling, which is part of why effects are subtle and inconsistent in studies.
Is it approved now that it's off Category 2?
No. Removal from Category 2 is procedural; DSIP awaits its July 2026 PCAC review and is not an approved medicine.
Sources
- Schoenenberger GA, Monnier M. Characterization of delta sleep-inducing peptide (DSIP).
- U.S. FDA — 503A bulk drug substances list update and Category 2 removals, April 15, 2026; PCAC meeting notice for July 23–24, 2026 (emideltide).
Medical disclaimer: Education only, not medical advice. DSIP is investigational and not approved for human use. Dosing figures reflect community reports, not a recommendation. Do not self-administer; consult a licensed clinician.